Clinical Trial Results:
A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic renal cell carcinoma (RCC)
Summary
|
|
EudraCT number |
2006-003137-32 |
Trial protocol |
IT |
Global completion date |
31 Oct 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Dec 2021
|
First version publication date |
03 Dec 2021
|
Other versions |
|
Summary report(s) |
Sorafenib_Pubblicazione |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.